Document ID: chunk:federal_register_of_legislation:F2025L00062:schedule:1:p44
Version: federal_register_of_legislation:F2025L00062
Segment Type: schedule
Provision Reference: sch 1 (pt 44/51)
Character Range: 134579–138129

Ltd                 21 663 385 411
XC    Southern Cross Pharma Pty Ltd                   47 094 447 677
XE    ACCELAGEN PTY LTD                               11 142 888 766
XH    MS Health Pty Ltd                               33 155 182 586
XI    Alexion Pharmaceuticals Australasia Pty Ltd     59 132 343 036
XN    Southern XP Pty Ltd                             34 639 505 481
XO    Echo Therapeutics Pty Ltd                       92 628 298 699
XT    Arrotex Pharmaceuticals Pty Ltd                 30 605 552 234
XW    Arrotex Pharmaceuticals Pty Ltd                 30 605 552 234
XY    MAXX PHARMA PTY LTD                             33 629 622 224
YG    EUGIA PHARMA (AUSTRALIA) PTY LTD                57 656 083 028
YN    Mayne Pharma International Pty Ltd              88 007 870 984
YO    The Trustee for ORSPEC PHARMA UNIT TRUST        15 634 980 417
YT    Mayne Products Pty Ltd                          59 140 866 379
ZB    Specialised Therapeutics Pm Pty Ltd             50 617 311 083
ZE    Seekwell Pty Ltd                                91 624 401 618
ZL    Specialised Therapeutics Pharma Pty Ltd         77 609 261 430
ZO    Swedish Orphan Biovitrum Pty Ltd                14 645 396 532
ZS    Strides Pharma Science Pty Ltd                  44 635 036 734
ZU    Seekwell Pty Ltd                                91 624 401 618

[182] Schedule 4, Part 1, omit entry for Circumstances Code "C5820"
[183] Schedule 4, Part 1, omit entry for Circumstances Code "C5840"
[184] Schedule 4, Part 1, omit entry for Circumstances Code "C5841"
[185] Schedule 4, Part 1, omit entry for Circumstances Code "C5854"
[186] Schedule 4, Part 1, omit entry for Circumstances Code "C6429"
[187] Schedule 4, Part 1, omit entry for Circumstances Code "C13431"
[188] Schedule 4, Part 1, omit entry for Circumstances Code "C13436"
[189] Schedule 4, Part 1, omit entry for Circumstances Code "C13887"
[190] Schedule 4, Part 1, entry for Circumstances Code "C15269"
omit from the column headed "Listed Drug": Saxagliptin with dapagliflozin
[191] Schedule 4, Part 1, entry for Circumstances Code "C15270"
omit from the column headed "Listed Drug": Saxagliptin with dapagliflozin
[192] Schedule 4, Part 1, omit entry for Circumstances Code "C16189"
[193] Schedule 4, Part 1, entry for Circumstances Code "C16226"
substitute:
C16226  P16226  CN16226  Somatropin  Severe growth hormone deficiency                                                                                                                                                                                                                                                    Compliance with Written Authority Required procedures
                                     Initial treatment of late onset growth hormone deficiency
                                     Must be treated by an endocrinologist.
                                     Patient must have onset of growth hormone deficiency secondary to organic hypothalamic or pituitary disease diagnosed at chronological age of 18 years or older; OR
                                     Patient must have onset of growth hormone deficiency diagnosed after skeletal maturity (bone age greater than or equal to 15.5 years in males or 13.5 years in females) and before chronological age of 18 years; AND
                                     Patient must have a diagnostic insulin tolerance test with maximum serum growth hormone (GH) less than 2.5 micrograms per litre; OR
                                     Patient must have a diagnostic arginine